Daily Sepsis Research Analysis
Three sepsis-focused papers stood out today: an updated meta-analysis supports serum neurogenic biomarkers for diagnosing and risk-stratifying sepsis-associated encephalopathy, and two mechanistic animal studies identify actionable pathways—Src/AKT1/NF-κB and HPA-axis metabolic remodeling—offering therapeutic leads (Norwogonin and Sini decoction). Together, they advance diagnostic precision and illuminate neuro-immune-endocrine mechanisms in sepsis.
Summary
Three sepsis-focused papers stood out today: an updated meta-analysis supports serum neurogenic biomarkers for diagnosing and risk-stratifying sepsis-associated encephalopathy, and two mechanistic animal studies identify actionable pathways—Src/AKT1/NF-κB and HPA-axis metabolic remodeling—offering therapeutic leads (Norwogonin and Sini decoction). Together, they advance diagnostic precision and illuminate neuro-immune-endocrine mechanisms in sepsis.
Research Themes
- Sepsis-associated encephalopathy diagnostics with serum neurogenic biomarkers
- Preclinical therapeutics targeting Src/AKT1/NF-κB signaling in sepsis-related lung injury
- Neuroendocrine-metabolic regulation of the HPA axis in experimental sepsis
Selected Articles
1. Unveiling neurogenic biomarkers for the differentiation between sepsis patients with or without encephalopathy: an updated meta-analysis.
This PROSPERO-registered, PRISMA-compliant meta-analysis of 42 studies found significantly higher serum NSE, UCH-L1, Tau, S100β, and GFAP levels in sepsis-associated encephalopathy compared with sepsis without encephalopathy. Lower NSE, UCH-L1, Tau, and S100β (but not GFAP) were observed in survivors versus non-survivors, supporting diagnostic and prognostic utility despite substantial heterogeneity.
Impact: Clarifies which neurogenic serum biomarkers track with SAE presence and mortality risk, offering a basis for standardizing diagnostic panels in ICU sepsis care.
Clinical Implications: Incorporating NSE, UCH-L1, Tau, and S100β into diagnostic pathways could enhance early identification and risk stratification of SAE. Standardization of sampling times, cutoffs, and assay platforms is needed before routine adoption.
Key Findings
- Serum NSE (SMD 1.98; 95% CI 1.55–2.42), UCH-L1 (SMD 1.75; 95% CI 0.90–2.59), Tau (SMD 1.14; 95% CI 1.01–1.28), S100β (SMD 1.82; 95% CI 1.45–2.19), and GFAP (SMD 3.63; 95% CI 1.85–5.41) were higher in SAE than in septic patients without encephalopathy.
- Survivors had lower NSE (SMD −1.87), UCH-L1 (SMD −1.71), Tau (SMD −0.57), and S100β (SMD −1.34) compared with non-survivors; GFAP differences were not significant for mortality.
- Protocol registered (CRD42023408312) with QUADAS-2 assessment; results limited by high heterogeneity across studies.
Methodological Strengths
- Registered protocol and PRISMA compliance with comprehensive multi-database search.
- Use of QUADAS-2 for study quality and pooled effect estimates with CIs.
Limitations
- High heterogeneity in study designs, SAE definitions, and sampling time points.
- Potential publication bias and predominance of observational data without standardized assays.
Future Directions: Prospective, standardized diagnostic accuracy studies with predefined thresholds, timing, and multi-marker panels; integration with EEG/clinical scores to build decision tools.
BACKGROUND: Sepsis-associated encephalopathy (SAE) is characterized by brain dysfunction in the context of sepsis and frequently leads to significant cognitive and neurological impairments, as well as an elevated risk of mortality. Accurate diagnosis of SAE is crucial for the timely initiation of optimal treatment and appropriate patient management. Neurogenic biomarkers hold promise as reliable serum diagnostic tools for the detection and longitudinal monitoring of SAE. This meta-analysis seeks to evaluate the diagnosti
2. Norwogonin attenuates LPS-induced acute lung injury through inhibiting Src/AKT1/NF-κB signaling pathway.
In an LPS-induced rat model of sepsis-related ALI, Norwogonin improved physiology, reduced vascular leak and leukocyte adhesion, suppressed NF-κB/NLRP3 signaling, and restored endothelial junction proteins. Network pharmacology, docking, SPR, and enzyme assays demonstrated direct binding and inhibition of Src, AKT1, and COX-2, implicating Src/AKT1/NF-κB pathway blockade as the mechanistic basis.
Impact: Identifies a multi-target small molecule with direct engagement of Src, AKT1, and COX-2 and in vivo efficacy in sepsis-related ALI, offering translatable targets for drug development.
Clinical Implications: While preclinical, the data support targeting Src/AKT1/NF-κB signaling in sepsis-related ALI. Existing inhibitors of these nodes or optimized Norwogonin analogs could be evaluated for safety and efficacy in clinically relevant models and early-phase trials.
Key Findings
- Norwogonin reduced leukocyte adhesion, FITC-dextran leakage, lung edema (W/D ratio), and inflammatory cytokines, improving arterial blood gases.
- Increased endothelial junction proteins and suppressed NF-κB/NLRP3 signaling in LPS-induced ALI.
- Direct binding to and inhibition of Src, AKT1, and COX-2 confirmed by surface plasmon resonance and enzyme activity assays; MMP-9 not directly bound.
Methodological Strengths
- Multimodal validation: in vivo physiology, imaging of microcirculation, molecular assays (WB/RT-qPCR).
- Target engagement demonstrated by SPR and enzyme activity assays, supporting mechanism-of-action.
Limitations
- LPS model may not capture polymicrobial sepsis complexity; survival outcomes not reported.
- Dose–response, pharmacokinetics, and safety/toxicity profiles are not delineated.
Future Directions: Assess dose–response, PK/PD, and safety; validate in cecal ligation and puncture or pneumonia models; explore combination with standard sepsis care and existing Src/AKT/COX-2 inhibitors.
BACKGROUND: Acute lung injury (ALI) has emerged as a critical illness, with sepsis-related ALI accounting for >80 %. In the context of bacterial infection, damage to the pulmonary microvascular barrier leads to inflammatory cell infiltration and plasma component extravasation into pulmonary interstitium. This disruption impairs gas exchange, resulting in hypoxemia. Norwogonin (NWG), a natural plant flavone, has shown potential anti-inflammatory and antioxidative effects. However, whether it could amelio
3. Sini decoction alleviates LPS-induced sepsis partly via restoration of metabolic impairments in the hypothalamic-pituitary-adrenal microenvironment.
In LPS-induced septic rats, Sini decoction reduced systemic inflammation and multi-organ injury, normalized HPA-axis hormones (CRH, ACTH, corticosterone), and remodeled HPA tissue metabolomes. Metabolic pathway regulation involved glycerophospholipid turnover, fatty acid β-oxidation, tryptophan and arachidonic acid metabolism, with protein changes (↓LPCAT1/IDO1; ↑CPT1A/FAAH1) supporting mechanism.
Impact: Links a traditional multi-component therapy to specific HPA-axis metabolic pathways in sepsis with multi-omics evidence, suggesting a neuroendocrine-metabolic therapeutic angle.
Clinical Implications: Although preclinical, the HPA-axis metabolic targets (e.g., LPCAT1, IDO1, CPT1A, FAAH1) present testable nodes for adjunctive modulation in sepsis. Component-focused optimization could aid translation.
Key Findings
- Sini decoction decreased IL-6 and TNF-α, reduced biochemical markers of multi-organ injury, and improved histopathology in heart, liver, spleen, lung, kidney, and HPA tissues in LPS sepsis.
- Normalized HPA-axis hormones (CRH, ACTH, corticosterone) and remodeled tissue metabolomes across glycerophospholipid, fatty acid β-oxidation, tryptophan, and arachidonic acid pathways.
- Western blot supported metabolic pathway regulation: ↓LPCAT1 and IDO1; ↑CPT1A and FAAH1; 40 and 23 components detected in serum and CSF, respectively.
Methodological Strengths
- Integrated metabolomics (UHPLC-Q-TOFMS) of HPA-axis tissues with hormonal, biochemical, and histopathology readouts.
- Detection of absorbed components in serum/CSF and pathway validation by western blot.
Limitations
- LPS rat model; lack of survival endpoints and dose–response; complex multi-component intervention complicates attribution.
- No direct comparison with standard sepsis therapies or endocrine modulators.
Future Directions: Dissect active constituents and synergistic pairs; test in polymicrobial models; evaluate whether targeted modulation of LPCAT1/IDO1/CPT1A/FAAH1 reproduces benefits.
ETHNOPHARMACOLOGICAL RELEVANCE: The hypothalamic-pituitary-adrenal (HPA) axis plays a vital role in the protection against sepsis. Sini decoction (SND) could improve HPA axis function. AIM OF THE STUDY: This work aimed to explore the effective mechanism of SND against lipopolysaccharide (LPS)-induced sepsis in rats from the metabolic regulation of the HPA axis microenvironment. MATERIALS AND METHODS: We evaluated the multiorgan injury-associated enzymatic indicators and histopathological changes as well as the ultrastructural changes in the hypothalamus, pituitary gland, and adrenal gland associated with LPS-induced sepsis. Serum inflammatory cytokines, corticotropin-releasing hormone (CRH), adrenocorticotropic hormone (ACTH) and corticosterone (CORT) were determined by ELISA. The target tissues metabolomics of the HPA axis (hypothalamus, pituitary gland, and adrenal gland), based on ultra-high performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UHPLC-Q-TOFMS), were conducted to dissect the metabolic network regulated by SND. Western blotting was further used to validate the key metabolic pathways. In addition, the absorbed chemical constituents in serum and cerebrospinal fluid were identified by UHPLC-Q-TOFMS combined with solid-phase extraction. RESULTS: Forty and twenty-three components of SND were absorbed into the serum and cerebrospinal fluid, respectively. SND could decrease multiorgan injury-associated indicators, including serum creatine kinase, urea nitrogen, creatinine, lactate dehydrogenase, alanine aminotransferase, and aspartate aminotransferase, inhibit inflammatory cytokines IL-6 and TNF-α, regulate the serum levels of CRH, ACTH and CORT in LPS-induced septic rats, and alleviate the sepsis-induced morphological changes in the heart, liver, spleen, lung, and kidney and HPA tissues. SND had the ability to regulate the unbalanced glycerophospholipid metabolism, fatty acid β-oxidation, fatty acid amide metabolism, tryptophan metabolism and arachidonic acid metabolism to improve the LPS-induced sepsis. The results of western blotting analysis demonstrated that SND could decrease the expressions of LPCAT1 and IDO1 and increase the expressions of CPT1A and FAAH1 to regulate the above metabolic disorders. CONCLUSION: SND could alleviate LPS-induced sepsis partly via restoration of metabolic impairments in the HPA axis microenvironment, which provided important insights to future work to ascertain the mechanisms undergoing the HPA axis response to SND against sepsis.